Table 1 The role and mechanism of m6A regulators in OC
m6A regulators | Roles | Genes/RNAs | Mechanisms | Model | Refs. |
|---|---|---|---|---|---|
Writers | |||||
METTL3 | Oncogene | AXL | METTL3 stimulates AXL translation and EMT | In vitro; in vivo | [30] |
METTL3 | Oncogene | AKT | METTL3 regulates the phosphorylation levels of AKT and the expression of the downstream effector Cyclin D1 | In vitro | [32] |
METTL3 | Oncogene | miR-126-5p | METTL3 promotes miR-126-5p maturation, leading to the activation of PTEN-mediated PI3K/Akt/mTOR pathway | In vitro; in vivo | [33] |
METTL3 | Oncogene | RHPN1-AS1 | METTL3 increases m6A level of lncRNA RHPN1-AS1 and contributes to its stability | In vitro; in vivo | [37] |
METTL14 | Tumor suppressor | TROAP | METTL14 negatively regulates TROAP expression in an m6A-dependent manner | In vitro; in vivo | [40] |
Readers | |||||
YTHDF1 | Oncogene | TRIM29 | YTHDF1 promotes TRIM29 translation, then affecting the CSC-like characteristics of OC cells | In vitro | [49] |
YTHDF1 | Oncogene | EIF3C | YTHDF1 promotes EIF3C’s translation in an m6A-dependent manner and affects the overall protein translation | In vitro; in vivo | [47] |
YTHDF2 | Oncogene | miR-145 | A double negative feedback loop between miR-145 and YTHDF2, regulates the proliferation and migration of OC cells | In vitro | [48] |
YTHDF2 | Oncogene | FBW7 | YTHDF2 is suppressed by FBW7, recognizes m6A-modifed BMF mRNA and accelerates decay of the latter | In vitro; in vivo | [45] |
IGF2BP1 | Oncogene | SRF | IGF2BP1 promotes SRF expression to augment SRF-dependent transcription | In vitro | [46] |
IGF2BP1 | Tumor suppressor | UBA6 | IGF2BP1 enhances the stability of UBA6 mRNA, thus inhibiting the malignancy of OC | In vitro | [51] |
Erasers | |||||
FTO | Tumor suppressor | PDE1C PDE4B | FTO reduces m6A level at the 3’UTR and the mRNA stability of PDE1C and PDE4B, thus blocking cAMP pathway | In vitro; In vivo | [53] |
FTO | unknown | ATG5/7 | circRAB11FIP1 promotes autophagy through FTO-mediated demethylation of ATG5 and ATG7 | In vitro | [57] |
Erasers | |||||
FTO/ALKBH5 | unknown | FZD10 | Downregulation of ALKBH5 and FTO contribute to PARPi resistance by increasing m6A modification in FZD10 mRNA to upregulate Wnt signaling | In vitro; in vivo | [56] |
ALKBH5 | Oncogene | NANOG | Highly expressed TLR4 activates NF-κB pathway, upregulates ALKBH5 expression and increases m6A level and NANOG expression | In vitro; in vivo | [54] |
ALKBH5 | Oncogene | JAK2 | ALKBH5-HOXA10 loop jointly activates the JAK2/STAT3 signaling pathway by mediating JAK2 m6A demethylation | In vitro; in vivo | [55] |
Immunoregulators | |||||
ZC3H13/YTHDF1/IGF2BP1 | NA | NA | Important immune cell infiltration-regulated m6A regulators | NA | [79] |